Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration

This post hoc analysis of 2 randomized clinical trials evaluates baseline and early treatment response factors associated with longer faricimab dosing intervals in patients with neovascular age-related macular degeneration.

Corresponding Author: Colin S. Tan, MBBS, Fundus Image Reading Center, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433 (colintan_eye@yahoo.com.sg).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.